AstraZeneca signals American pivot with £37bn US investment amid London listing concerns

AstraZenecas chief executive has described the pharmaceutical giant as a very American company following rising speculation about a potential shift of its main stock market listing from London to New York. Speaking from New York after publishing the companys half year results Sir Pascal Soriot highlighted Americas pivotal role and AstraZenecas deep roots in the US just a week after revealing plans to invest £37bn in the country by the end of the decade.

Soriot noted that while AstraZeneca remains global and is proudly headquartered in the UK historic perceptions of the business as solely British are outdated. He emphasised the companys significant presence not only in the United States but also in China Japan and across the globe reflecting a dynamic international strategy. AstraZeneca was created in 1999 from the merger of Swedens Astra AB and Britains Zeneca PLC and since then has maintained its global headquarters in the UK.

Reports have swirled about AstraZeneca possibly seeking a US primary listing a move that would deal a substantial blow to the City of London given its status as the largest company on the London Stock Exchange. Soriot declined to address the reports directly but reiterated the multinational and American nature of the company which recently announced a $50bn investment in the US. The move comes on the heels of pressure from former US president Donald Trump for drug manufacturers to bolster American medicine production. Trump has also repeatedly criticised the high cost of pharmaceuticals in the US compared to other countries.

AstraZeneca has responded to this climate by proposing lowered prices for some of its US products as part of a broader global price rebalancing. Soriot acknowledged the push for price equalisation and noted that reductions in the US could be paired with increases in Europe. After AstraZeneca unveiled its strong half yearly revenues which climbed 11 percent to nearly $28bn shares surged by up to three percent reflecting investor confidence amidst the shifting landscape.

Soriots remarks underscore AstraZenecas transformation into a truly international pharmaceutical powerhouse with a sharpened focus on innovation and expansion in key global markets. London faces an uphill battle to retain high profile listings as internationally minded firms look increasingly across the Atlantic for capital and growth opportunities.